XALIVA THC
Commercial- Indications
- Cannabis detection
Company intelligence / Profile preview
Ricovr Healthcare has developed the Xaliva rapid diagnostics platform—a saliva-based biosensor technology providing fast and accurate point-of-care results. Their lead product detects recent cannabis use via THC in oral fluid and aims to address workplace safety and fairness issues. The company has also demonstrated proof-of-concept for COVID‑19 antigen detection using the same core technology. Early validation studies have shown high sensitivity and specificity in biomarker identification; commercial launch efforts are underway for the THC test while additional tests are in development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ricovr Healthcare.